Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CRBP Stock Price Chart
Explore Corbus Pharmaceuticals Holdings, Inc. interactive price chart. Choose custom timeframes to analyze CRBP price movements and trends.
CRBP Company Profile
Discover essential business fundamentals and corporate details for Corbus Pharmaceuticals Holdings, Inc. (CRBP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Oct 2014
Employees
36.00
Website
https://www.corbuspharma.comCEO
Yuval Cohen
Description
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP Financial Timeline
Browse a chronological timeline of Corbus Pharmaceuticals Holdings, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$1.30.
Earnings released on 12 May 2026
EPS came in at -$1.23 surpassing the estimated -$1.26 by +2.38%.
Earnings released on 9 Mar 2026
EPS came in at -$1.25 surpassing the estimated -$1.78 by +29.78%.
Earnings released on 12 Nov 2025
EPS came in at -$1.90 falling short of the estimated -$1.80 by -5.56%.
Earnings released on 5 Aug 2025
EPS came in at -$1.44 surpassing the estimated -$1.55 by +7.10%.
Earnings released on 6 May 2025
EPS came in at -$1.39 falling short of the estimated -$1.26 by -10.32%.
Earnings released on 11 Mar 2025
EPS came in at -$0.78 surpassing the estimated -$1.02 by +23.53%.
Earnings released on 7 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$0.99 by -16.16%.
Earnings released on 6 Aug 2024
EPS came in at -$0.90 surpassing the estimated -$1.16 by +22.41%.
Earnings released on 7 May 2024
EPS came in at -$0.83 surpassing the estimated -$1.09 by +23.85%.
Earnings released on 12 Mar 2024
EPS came in at -$1.81 surpassing the estimated -$2.36 by +23.31%, while revenue for the quarter reached $1.35m .
Earnings released on 7 Nov 2023
EPS came in at -$2.27 falling short of the estimated -$2.06 by -10.19%.
Earnings released on 8 Aug 2023
EPS came in at -$2.05 surpassing the estimated -$3.10 by +33.87%.
Earnings released on 9 May 2023
EPS came in at -$4.24 falling short of the estimated -$4.09 by -3.67%.
Earnings released on 7 Mar 2023
EPS came in at -$2.61 falling short of the estimated -$2.10 by -24.29%.
Stock split effective on 14 Feb 2023
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2022
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 9 Aug 2022
EPS came in at -$2.10 falling short of the estimated -$1.80 by -16.67%.
Earnings released on 10 May 2022
EPS came in at -$2.40 surpassing the estimated -$2.70 by +11.11%.
Earnings released on 8 Mar 2022
EPS came in at -$2.40 surpassing the estimated -$3.30 by +27.27%, while revenue for the quarter reached -$881.71k , missing expectations by -353.73%.
Earnings released on 12 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$3.60 by +83.33%, while revenue for the quarter reached $97.32k , missing expectations by -84.05%.
Earnings released on 12 Aug 2021
EPS came in at -$4.50 falling short of the estimated -$3.60 by -25.00%, while revenue for the quarter reached $136.56k , missing expectations by -0.32%.
CRBP Stock Performance
Access detailed CRBP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
